Saturday, December 22, 2018 1:30:47 PM
A2-73 ~66% mouse at 10 mg/kg
Donepezil 93% rat at 10 mg/kg
PET data shows S1R occupancy is dose-dependent for ANAVEX®2-73 with a plateau at 68% ± 11% in whole brain
https://www.anavex.com/wp-content/uploads/2018/07/AAIC_2018-PET_Anavex_Final.pdf
Figure 1. Static image of PET scan of ANAVEX®2-73 in mouse at time 15-20 minutes at the following drug doses: A = WT control, B = 1 mg/kg ANAVEX®2-73, C = 10 mg/kg ANAVEX®2-73 and D = 30 mg/kg ANAVEX®2-73.
Table 1. This table summarizes binding potential and distribution volume values calculated using 2TCM and the calculated percent receptor occupancy.
1 mg/kg ANAVEX®2-73 0.81 ± 0.11 13.6 ± 2.1 20.8 ± 10.8
10 mg/kg ANAVEX®2-73 0.34 ± 0.09 7.9 ± 1.8
66.7 ± 9.1
30 mg/kg ANAVEX®2-73 0.32 ± 0.11 8.2 ± 1.8 68.3 ± 10.6 1 mg/kg PRE-084 0.93 ± 0.19 14.6 ± 1.5 8.4 ± 18.5
https://rd.springer.com/article/10.1007%2Fs00213-014-3533-2
Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11C-SA4503 and microPET
RO increased dose-dependently and was 93 % at 10 mg/kg. ED50 was 1.29 mg/kg.
Donepezil 93% rat at 10 mg/kg
PET data shows S1R occupancy is dose-dependent for ANAVEX®2-73 with a plateau at 68% ± 11% in whole brain
https://www.anavex.com/wp-content/uploads/2018/07/AAIC_2018-PET_Anavex_Final.pdf
Figure 1. Static image of PET scan of ANAVEX®2-73 in mouse at time 15-20 minutes at the following drug doses: A = WT control, B = 1 mg/kg ANAVEX®2-73, C = 10 mg/kg ANAVEX®2-73 and D = 30 mg/kg ANAVEX®2-73.
Table 1. This table summarizes binding potential and distribution volume values calculated using 2TCM and the calculated percent receptor occupancy.
1 mg/kg ANAVEX®2-73 0.81 ± 0.11 13.6 ± 2.1 20.8 ± 10.8
10 mg/kg ANAVEX®2-73 0.34 ± 0.09 7.9 ± 1.8
66.7 ± 9.1
30 mg/kg ANAVEX®2-73 0.32 ± 0.11 8.2 ± 1.8 68.3 ± 10.6 1 mg/kg PRE-084 0.93 ± 0.19 14.6 ± 1.5 8.4 ± 18.5
https://rd.springer.com/article/10.1007%2Fs00213-014-3533-2
Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11C-SA4503 and microPET
RO increased dose-dependently and was 93 % at 10 mg/kg. ED50 was 1.29 mg/kg.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

